| Execution period | July 13, 2026 to July 12, 2029 |
|---|
BSE filing, NSE: KISSHT. Summary written from the filing by ALFA Finder's alert engine.
OnEMI Technology Solutions Ltd: key numbers
- Share price
- ₹316.10
- Market cap
- ₹6,468 Cr
- Revenue (annual)
- ₹2,179 Cr
- Net profit (annual)
- ₹281.4 Cr
- P/E (TTM)
- 17.0×Sector 19.7×
- Promoter holding
- 20.42%-4.38% QoQ
- FII holding
- 9.95%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from OnEMI Technology Solutions Ltd
All →OnEMI Technology Solutions Results Update
Kissht reported Q2FY27 PAT of ₹125 Crore, doubling year-on-year, with AUM up 68% to ₹9,317 Crore. Press release accompanies unaudited Q2 and H1 FY27 results.
OnEMI Technology Solutions Investor Presentation: Key Takeaways
Q2 FY27: AUM ₹9,317 Cr (+68% YoY), PAT ₹125 Cr (+100% YoY), RoAAUM 5.78%, GNPA 2.18%. AUM growth guidance raised to 60%+ from 40%+.
OnEMI Technology Solutions Business Update
OnEMI Technology Solutions (Kissht) disclosed its Key Performance Indicators for the quarter ended 30 September 2026. The KPIs, including those defined in its May 2026 prospectus, are published on the company website.
OnEMI Technology Solutions Capital Structure Change
OnEMI will invest ₹624.15 Crore in its wholly owned subsidiary Si Creva via rights subscription. Funds come from preferential issue proceeds, completing by December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
OnEMI Technology Solutions Acquisition Worth ₹624.1 Cr
OnEMI Technology's board approved a Rs.624.15 Crore cash investment in Si Creva Capital Services, subscribing 23,37,516 equity shares at Rs.2,670.14 each. Completion is indicated by end-December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
OnEMI Technology Solutions Q2 FY27 Results: Net Profit ₹125.1 Cr, Up 100.5% YoY
OnEMI Technology Solutions Ltd reported revenue from operations of ₹731.8 Cr (+44.7% YoY) and net profit of ₹125.1 Cr (+100.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹125.1 Cr · +100.5% YoY
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.